Lyka Labs' Q4 loss is ₹29.77 cr. Most of it was already known.

Tipsheet Editorial — Mon, 25 May 2026 15:47:47 GMT

A ₹23 cr subsidiary impairment, disclosed earlier, eats up the bulk of the quarter's net loss. The results confirm old news.

What’s new

Lyka Labs approved Q4 and FY26 audited results; standalone net loss was ₹29.77 cr.
The loss was driven by a ₹23.01 cr impairment in subsidiary Lyka BDR International.
Revenue was broadly stable quarter-on-quarter.

Why it matters

A ₹29.77 crore net loss looks alarming until you see that ₹23.01 crore of it is an impairment charge the company already told the market about. Strip that out, and the underlying operational loss is much smaller. The results confirm the bad news, not break it.

What we’re watching

Any future steps to restructure or sell Lyka BDR International post-impairment.
How the amalgamation scheme, now past its record date, reshapes the group structure.
Trend in operational revenue and costs once the one-off write-down is behind the numbers.

The full read

Lyka Labs' Q4 loss is ₹29.77 crore. Mostly noise. ₹23.01 crore of it is a subsidiary impairment at Lyka BDR International, a hit the company had already flagged. Revenue was broadly stable. The filing also processed a record date for the group amalgamation and set the AGM. What remains is the operational story. Strip out the known write-down, and the loss shrinks dramatically. The real question is what happens to Lyka BDR now.

Primary source: BSE · NSE

Lyka Labs writes off ₹23 cr in subsidiary, posts annual loss

Tipsheet Editorial — Mon, 25 May 2026 15:39:56 GMT

The nano-cap's Q4 impairment charge wipes out the value of its investment in Lyka BDR International, turning a full-year profit into a loss.

What’s new

Lyka Labs took a ₹23 crore impairment on its stake in Lyka BDR International, reducing its carrying value to zero.
The standalone net loss for Q4 was ₹29.8 crore, compared to a profit of ₹7.9 crore in FY25.
Annual revenue fell to ₹28 crore from ₹30.5 crore in the prior year.

Why it matters

For a company with a ₹220 crore market cap, a ₹23 crore write-down is material. It flips the annual result from profit to loss and signals that a key subsidiary is effectively worthless. The loss is now crystallised on the balance sheet.

What we’re watching

Any strategic plan for the subsidiary now valued at zero.
The impact of the amalgamation scheme whose record date was set.
Whether Lyka Labs can return to profitability without this drag.

The full read

Lyka Labs wrote off its entire ₹23 crore exposure to subsidiary Lyka BDR International. The impairment charge drove the company to a standalone net loss of ₹29.8 crore in Q4 and a full-year loss of ₹32.3 crore, erasing the ₹7.9 crore profit it posted in FY25. For a company with a ₹220 crore market cap, the charge alone is worth 10.5% of its equity value. Lyka BDR's continuous operational losses made the write-down inevitable; the subsidiary's carrying value is now zero. The other board action, setting a record date for shares under its amalgamation scheme, is procedural. The story here is the impairment. A nano-cap just told you a chunk of its balance sheet is worthless.

Primary source: BSE · NSE

Lyka Labs Ltd. (LYKALABS) — Tipsheet

Lyka Labs' Q4 loss is ₹29.77 cr. Most of it was already known.

What’s new

Why it matters

What we’re watching

The full read

Lyka Labs writes off ₹23 cr in subsidiary, posts annual loss

What’s new

Why it matters

What we’re watching

The full read